Two additional retatrutide Phase 3 trials reported
Lilly announced topline results from TRIUMPH-2 and TRIUMPH-3. Retatrutide remains investigational and is not approved by a regulatory authority.
Primary source ↗A LOOK AT METABOLIC PEPTIDES
Peptides.
Clinical context
in 2026.
Retatrutide, cagrilintide, survodutide, zenagamtide and MariTide. See how they differ, what their programmes study and where the clinical science stands.
Educational guide. Treatment choices belong in a conversation with a clinician.
Conceptual molecular illustration
03
GLP-1 · GIP · glucagonReceptor targets studied with retatrutide
IMPORTANT PRODUCT NOTE
External research catalogues may include materials labelled for laboratory research only. They are not presented here as medicines, personal-use products or approved therapeutic products.
01 / WHAT’S NEW
Research and
regulatory updates.
New molecules, trial results, regulatory filings and approvals, ordered by publication date and linked to primary sources.
Novo Nordisk presented new CagriSema and zenagamtide data
The company announced additional Phase 3 CagriSema results and mid-stage data for investigational zenagamtide ahead of ADA 2026.
Primary source ↗CagriSema submitted for FDA review
Novo Nordisk filed a US application for weight management. A filing is not an approval; CagriSema remains investigational while the review is pending.
Primary source ↗A trial result or regulatory filing is not an approval. We will label an approval only after publication by the relevant regulator.
02 / RESEARCH CATALOGUE
CertaPeptides.
A catalogue for research.
Check the selected batch documentation and use the code for 10% off at checkout.
ADVERTISING PARTNERSHIP · CERTAPEPTIDES
Your next study.
10% off.
Peptides for in-vitro research and laboratory use only. Not for human use.
Code at checkout AFF-PEPTIDEATLAS
Explore CertaPeptides 10% with the code. Merchant terms apply.Partner links may earn PeptideAtlas a commission at no extra cost to you.
03 / MOLECULES IN FOCUS
Five current programmes
in clinical focus.
These profiles describe molecules in clinical development. Trial data do not establish the quality or safety of products sold by online stores.
Retatrutide
GLP-1 + GIP + glucagon
A triple receptor agonist studied in obesity and related conditions. Lilly describes it as an investigational molecule that is not yet approved for use.
Survodutide
GLP-1 + glucagon
A dual receptor agonist studied in overweight and obesity. The clinical programme evaluates both efficacy and safety.
Cagrilintide
Amylin analogue
A different hormonal approach studied alone and with semaglutide. CagriSema is a separate investigational combination; its results are not results for cagrilintide alone.
Zenagamtide (amycretin)
GLP-1 + amylin
A unimolecular GLP-1 and amylin receptor agonist. Novo Nordisk describes zenagamtide (amycretin) as an investigational molecule in clinical development, including Phase 3 programmes; it is not an approved medicine.
MariTide (maridebart cafraglutide)
GLP-1 + GIPR antagonism
An antibody-peptide conjugate studied in the MARITIME programme. Amgen describes MariTide as an investigational molecule in Phase 3; a clinical programme is not regulatory approval.
These profiles are not a ranking and are not a recommendation for use. Regulatory status can change.
04 / CLINICAL DATA IN NUMBERS
Results
need context.
These are results from specific trials, doses and time periods. They are not a promise of an individual outcome and do not validate products sold through an online catalogue.
mean weight change
At 48 weeks at the highest studied dose, compared with −2.1% for placebo.
NEJM ↗on-treatment analysis
At 46 weeks at 4.8 mg; the planned-treatment analysis was −14.9% versus −2.8% for placebo.
PubMed ↗at 68 weeks
REDEFINE 1 reported −20.4% in the treatment-policy analysis; −22.7% was the estimate if all participants adhered to treatment.
Novo Nordisk ↗HOW TO READ THEM
Different molecules, doses, participants and analyses should not be turned into a simple ranking. Investigational programmes and research-only catalogue products are separate categories.
05 / HOW TO READ THE DATA
Beyond
weight-loss
percentages.
Trial results depend on the participants, duration and analysis method. A percentage alone is not enough for a comparison.
Example of regulatory assessment: EMA ↗Who was studied?
Check whether participants had diabetes, the inclusion criteria and how long they were followed.
What was the comparison?
A placebo comparison and a head-to-head medicine trial answer different questions.
What were the risks?
Adverse events and treatment discontinuation are part of the assessment. Results do not guarantee an individual effect.
06 / APPROVED MEDICINES
A molecule's name
is not authorization
for use.
In the EU, specific prescription medicines are approved for weight management. That approval does not transfer to other products with a similar name or composition.
Semaglutide
Wegovy — a prescription medicine with weight-management indications for defined patient groups.
Indications and risks at EMA ↗Tirzepatide
Mounjaro — a prescription medicine with indications that include weight management in defined adult groups.
Indications and risks at EMA ↗These are regulatory examples, not an offer of sale or individual treatment advice. Discuss options with a clinician.
07 / OTHER AREAS
Peptides are
more than weight.
Peptide science includes approved medicines and investigational programmes across many fields. This is a map of research, not a product list.
Diabetes and metabolic health
Insulin, GLP-1 and combination molecules are studied for glucose control, appetite and metabolic risk.
Bone health
Peptide hormone analogues, including PTH-based therapies, are part of medicine development for bone loss.
Oncology and targeting
Peptide carriers and peptide-drug conjugates are studied to deliver active molecules more precisely.
Tissue repair
Peptides and growth factors are investigated for chronic wounds and tissue repair, with different clinical statuses.
Overview of therapeutic areas: PubMed review ↗ EMA links point to approved medicines for defined indications.
09 / FAQ
Before you
continue.
Which peptide is best for weight loss?
There is no universal choice. Approved indications, contraindications, other conditions and monitoring matter. A clinician can assess treatment options. Results from different trials are not automatically comparable.
Is retatrutide an approved medicine?
Retatrutide is an investigational molecule in clinical development and is not approved for use. A published trial result is not authorization to sell it as a medicine.
Can research-only catalogue products be used for weight loss?
No. Materials labelled for research use are not presented here as medicines or as products for personal use. A certificate of analysis does not turn them into approved medicines.
Why are external catalogues mentioned?
PeptideAtlas explains the research context and documentation before a visitor follows the clearly marked active catalogue link. The site does not rank products or present research materials as medicines.
How is my data used here?
There are no registration forms or advertising pixels. We use Umami for aggregate measurement of visits and partner clicks without cookies. External websites have their own policies.